These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

832 related items for PubMed ID: 18310206

  • 1. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life.
    Adamkiewicz TV, Silk BJ, Howgate J, Baughman W, Strayhorn G, Sullivan K, Farley MM.
    Pediatrics; 2008 Mar; 121(3):562-9. PubMed ID: 18310206
    [Abstract] [Full Text] [Related]

  • 2. Herd immunity and pneumococcal conjugate vaccine: a quantitative model.
    Haber M, Barskey A, Baughman W, Barker L, Whitney CG, Shaw KM, Orenstein W, Stephens DS.
    Vaccine; 2007 Jul 20; 25(29):5390-8. PubMed ID: 17583392
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects.
    Lloyd A, Patel N, Scott DA, Runge C, Claes C, Rose M.
    Eur J Health Econ; 2008 Feb 20; 9(1):7-15. PubMed ID: 17333089
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway.
    Vestrheim DF, Løvoll O, Aaberge IS, Caugant DA, Høiby EA, Bakke H, Bergsaker MR.
    Vaccine; 2008 Jun 19; 26(26):3277-81. PubMed ID: 18456376
    [Abstract] [Full Text] [Related]

  • 5. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 2005 Sep 16; 54(36):893-7. PubMed ID: 16163262
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
    Tyo KR, Rosen MM, Zeng W, Yap M, Pwee KH, Ang LW, Shepard DS.
    Vaccine; 2011 Sep 02; 29(38):6686-94. PubMed ID: 21745516
    [Abstract] [Full Text] [Related]

  • 7. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T, Abrahamsen TG, Bergsaker MA, Løvoll Ø, Møller P, Pedersen MK, Kristiansen IS.
    Vaccine; 2006 Jul 17; 24(29-30):5690-9. PubMed ID: 16735083
    [Abstract] [Full Text] [Related]

  • 8. Effect of community-wide conjugate pneumococcal vaccine use in infancy on nasopharyngeal carriage through 3 years of age: a cross-sectional study in a high-risk population.
    Millar EV, O'Brien KL, Watt JP, Bronsdon MA, Dallas J, Whitney CG, Reid R, Santosham M.
    Clin Infect Dis; 2006 Jul 01; 43(1):8-15. PubMed ID: 16758412
    [Abstract] [Full Text] [Related]

  • 9. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine.
    Halasa NB, Shankar SM, Talbot TR, Arbogast PG, Mitchel EF, Wang WC, Schaffner W, Craig AS, Griffin MR.
    Clin Infect Dis; 2007 Jun 01; 44(11):1428-33. PubMed ID: 17479937
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998-2005.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 2008 Feb 15; 57(6):144-8. PubMed ID: 18272956
    [Abstract] [Full Text] [Related]

  • 12. Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine.
    Black S, France EK, Isaacman D, Bracken L, Lewis E, Hansen J, Fireman B, Austrian R, Graepel J, Gray S, Klein NP.
    Pediatr Infect Dis J; 2007 Sep 15; 26(9):771-7. PubMed ID: 17721369
    [Abstract] [Full Text] [Related]

  • 13. Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine.
    Albrich WC, Baughman W, Schmotzer B, Farley MM.
    Clin Infect Dis; 2007 Jun 15; 44(12):1569-76. PubMed ID: 17516400
    [Abstract] [Full Text] [Related]

  • 14. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.
    Lacapa R, Bliss SJ, Larzelere-Hinton F, Eagle KJ, McGinty DJ, Parkinson AJ, Santosham M, Craig MJ, O'Brien KL.
    Clin Infect Dis; 2008 Aug 15; 47(4):476-84. PubMed ID: 18627249
    [Abstract] [Full Text] [Related]

  • 15. Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 2010 Mar 12; 59(9):253-7. PubMed ID: 20224541
    [Abstract] [Full Text] [Related]

  • 16. Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine.
    Poehling KA, Szilagyi PG, Grijalva CG, Martin SW, LaFleur B, Mitchel E, Barth RD, Nuorti JP, Griffin MR.
    Pediatrics; 2007 Apr 12; 119(4):707-15. PubMed ID: 17403841
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination.
    Adamkiewicz TV, Sarnaik S, Buchanan GR, Iyer RV, Miller ST, Pegelow CH, Rogers ZR, Vichinsky E, Elliott J, Facklam RR, O'Brien KL, Schwartz B, Van Beneden CA, Cannon MJ, Eckman JR, Keyserling H, Sullivan K, Wong WY, Wang WC.
    J Pediatr; 2003 Oct 12; 143(4):438-44. PubMed ID: 14571216
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Immunogenicity and safety of a pneumococcal conjugate 7-valent vaccine in infants with sickle cell disease.
    Reinert P, Benkerrou M, de Montalembert M, Lesprit E, Abadie I, Bernaudin F, Doit C, Bingen E, Tetelboum R, Bonnet E.
    Pediatr Infect Dis J; 2007 Dec 12; 26(12):1105-9. PubMed ID: 18043446
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.